Novo sets sights on obesity market with diabetes drug
Play all audios:
Access through your institution Buy or subscribe Novo aims to catch this wave of new mechanism drugs. As a statement of intent, shortly after the EMDAC hearing, it named Kevin Grove,
formerly of the Oregon Health & Science University, in Portland, as the head of its new obesity research center in Seattle. Bruce Spiegelman, of Harvard Medical School, in Boston, and
several other influential obesity researchers have, with backing from Boston-based Third Rock Ventures, founded Watertown, Massachusetts–based Ember Therapeutics, to develop new therapies
based on insights into the biology of brown fat tissue, which burns rather than stores fat. This effort is still at the preclinical stage, however. The upside for Novo is that liraglutide is
quite a well-known quantity. The drug—a glucagon-like peptide-1 (GLP-1) agonist—was approved at three lower doses, (0.6, 1.2 and 1.8 mg daily), for treating type 2 diabetes in Europe in
2009 and in the US in 2010. Sold under the Victoza brand, it attained just over $1 billion in sales during the first half of 2014. Rune Majlund Dahl, analyst at DNB Markets, of Oslo, says
Novo Nordisk has been cautious in its sales forecasts of the drug in obesity, with the consensus estimated at DKK3,924 billion ($668 million) in 2019. DNB is more bullish about its
prospects, given the scale of the opportunity. About 35% of the US adult population is now clinically obese, according to a recent report from the Paris-based think tank the Organisation for
Economic Co-operation and Development (OECD). “We estimate DKK 6,799 million, 73% above consensus,” he wrote in a recent research report. This is a preview of subscription content, access
via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy
this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *
Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Dublin Cormac Sheridan Authors * Cormac Sheridan
View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sheridan, C. Novo
sets sights on obesity market with diabetes drug. _Nat Biotechnol_ 32, 1071–1072 (2014). https://doi.org/10.1038/nbt1114-1071 Download citation * Published: 07 November 2014 * Issue Date:
November 2014 * DOI: https://doi.org/10.1038/nbt1114-1071 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable
link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative